Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Novo’s Rybelsus in for Price Cuts as Chuikyo OKs CEA Results
July 21, 2022
- Nuvaxovid Gets Label Update to Allow Primary Inoculations in Ages 12 and Older
July 21, 2022
- Japan Again Takes Pass on Emergency Approval for Shionogi’s COVID Pill as Panels Nix Presumed Efficacy
July 21, 2022
- Guidelines for Securing Key Resources Endorsed by LDP, Up for Cabinet Approval
July 20, 2022
- MHLW Official Sees More “Specified Clinical Research” Data Used in Regulatory Submissions to Fill Industry-Academia Void
July 20, 2022
- PMDA Head Fujiwara Re-Elected as ICMRA Vice Chair
July 20, 2022
- Taisho/Ablynx’s RA Med, BI’s Psoriasis Drug Up for MHLW Panel Review on July 29
July 19, 2022
- Japan Panel to Discuss 4th COVID Shot to Healthcare Providers: Health Minister
July 19, 2022
- MHLW Eyes Expert Panel Launch This Summer for Drug Distribution and Pricing: Official
July 19, 2022
- Japan Plans to Lower Minimum Age for Novavax Jab to 12
July 19, 2022
- MHLW Mulls Data Collection Policy for Conditionally Approved MSC Therapies
July 14, 2022
- Shionogi’s COVID-19 Pill Up for Expert Redeliberation on July 20
July 14, 2022
- Govt Council Calls for Steps to Beef Up Japan’s Clinical Trial System for Vaccines
July 13, 2022
- Accelerate Social Implementation of Genomic Medicine: Study Group
July 13, 2022
- 92 Defects/Health Damages Reported for Kymriah in October-March
July 13, 2022
- All 10 Pharma-Backed Candidates Grab Upper House Seats
July 12, 2022
- Japan Detects 4 More Probable Cases of Pediatric Hepatitis
July 11, 2022
- After Abe’s Death, Pharma and Medical Circles Fret Shift to Austerity and Tougher Drug Pricing
July 11, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
July 11, 2022
- Label Revision Ordered for Novavax Jab to Add Myocarditis Risks
July 11, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…